[1] KANDA T, ISHⅡ K, KAWAGUCHI H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material[J]. Radiology,2014,270(3):834-841. doi:  10.1148/radiol.13131669
[2] ROBERTS D R, HOLDEN K R. Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast[J]. Brain Dev,2016,38(3):331-336. doi:  10.1016/j.braindev.2015.08.009
[3] RADBRUCH A, WEBERLING L D, KIESLICH P J, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent[J]. Radiology,2015,275(3):783-791. doi:  10.1148/radiol.2015150337
[4] ROBERT P, LEHERICY S, GRAND S, et al. T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents[J]. Invest Radiol,2015,50(8):473-480. doi:  10.1097/RLI.0000000000000181
[5] ROBERT P, VIOLAS X, GRAND S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats[J]. Invest Radiol,2016,51(2):73-82. doi:  10.1097/RLI.0000000000000241
[6] LOHRKE J, FRISK A L, FRENZEL T, et al. Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents[J]. Invest Radiol,2017,52(6):324-333. doi:  10.1097/RLI.0000000000000344
[7] FDA. Gadolinium-based contrast agents for magnetic resonance imaging (MRI): drug safety communication—FDA evaluating the risk of brain deposits with repeated use[EB/OL]. (2017-05-23)[2019-08-13] https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm456012.htm.
[8] E M Agency.PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations. pdf[EB/OL]. (2017-03-10)[ 2019-08-13] http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/03/WC500223209.
[9] 食药监总局. 总局提示关注含钆对比剂反复使用引起脑部钆沉积的风险[EB/OL].(2017-12-06)[2019-08-13].http://samr.cfda.gov.cn/WS01/CL0050/218164.html
[10] 食药监总局. 药品不良反应信息通报(第76期) 关注含钆对比剂反复使用引起脑部钆沉积风险[EB/OL]. (2017-12-06)[2019-08-13]. http://samr.cfda.gov.cn/WS01/CL1989/218163.html
[11] FRENZEL T, LENGSFELD P, SCHIRMER H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C[J]. Invest Radiol,2008,43(12):817-828. doi:  10.1097/RLI.0b013e3181852171